Professional resources

FOR RENAL
DIETITIANS
LEARN MORE

Real-world analyses

DW Coyne, et al: 2017

Six months’ experience with Velphoro in a real-world setting: a retrospective analysis of pharmacy data.
SEE THE DATA
J Kendrick, et al: 2019

An in-center study of the real-world effectiveness of Velphoro over 1 year, with patients switched from other phosphate binder therapies.
SEE THE DATA
K Gray, et al: 2019

An analysis from a different large dialysis organization shows results consistent with other real-world data.
SEE THE DATA
K Kalantar-Zadeh, et al: 2018

A 6-month, real-world analysis of Velphoro in patients on peritoneal dialysis.
SEE THE DATA

Phase 3 trial results

J Floege, et al: 2014

Read the results of the open-label, randomized, active-controlled Phase 3 study that demonstrated the effectiveness of Velphoro in phosphate management.
SEE THE DATA
J Floege, et al: 2015

The results of a 28-week extension of the 2014 study, with patients who continued with the same treatment and dose they received at the end of the initial study.
SEE THE DATA

Connecting to Velphoro

Request samples of Velphoro
GET THE FORM
Link up with Velphoro Access Solutions
GET THE Application

Patient resources

Velphoro Patient Brochure

An easy-to-read, patient-friendly presentation of the Velphoro story.
GET THE BROCHURE
Velphoro Patient Quick Start Guide

Starting Velphoro explained in several quick steps.
GET THE QUICK START GUIDE
Phosphorus Food Guide

A handy list of foods to choose, and those to avoid.
GET THE FOOD GUIDE
Velphoro Points Program

The program for patients on Velphoro that educates and rewards adherence.
Visit VELPHORO Points

Resources for Renal Dietitians

More resources are available that are customized especially for you.

LEARN MORE

INDICATION

Velphoro^® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451